Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM61713 in T790M-positive NSCLC
NCT02485652Phase 2Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 2 trial of olmutinib in non-small cell lung cancer (NSCLC), sponsored by Hanmi Pharmaceutical. Started Aug 2015; status: terminated.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02485652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485652.